St. Jude Medical, Inc. Draws Bearish Options Activity Today

 St. Jude Medical, Inc. Draws Bearish Options Activity Today

In today’s session St. Jude Medical, Inc. (STJ) recorded an unusually high (726) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious STJ decrease. With 726 contracts traded and 11484 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: STJ161216P00075000 closed last at: $0.85 or 30.8% up. The stock increased 1.41% or $1.11 on November 23, hitting $80.02. About 2.87 million shares traded hands or 19.09% up from the average. St. Jude Medical, Inc. (NYSE:STJ) has risen 31.89% since April 22, 2016 and is uptrending. It has outperformed by 26.48% the S&P500.

Analysts await St. Jude Medical, Inc. (NYSE:STJ) to report earnings on January, 25. They expect $1.07 EPS, up 4.90% or $0.05 from last year’s $1.02 per share. STJ’s profit will be $300.46 million for 18.70 P/E if the $1.07 EPS becomes a reality. After $0.99 actual EPS reported by St. Jude Medical, Inc. for the previous quarter, Wall Street now forecasts 8.08% EPS growth.

St. Jude Medical, Inc. (NYSE:STJ) Ratings Coverage

Out of 20 analysts covering St. Jude Medical Inc. (NYSE:STJ), 4 rate it a “Buy”, 0 “Sell”, while 16 “Hold”. This means 20% are positive. St. Jude Medical Inc. has been the topic of 45 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of St. Jude Medical, Inc. (NYSE:STJ) has “Outperform” rating given on Thursday, October 22 by Credit Suisse. As per Monday, July 11, the company rating was downgraded by Leerink Swann. The stock of St. Jude Medical, Inc. (NYSE:STJ) earned “Market Perform” rating by BMO Capital Markets on Thursday, July 23. The stock of St. Jude Medical, Inc. (NYSE:STJ) has “Buy” rating given on Friday, August 28 by S&P Research. The firm earned “Hold” rating on Tuesday, September 1 by Evercore. The firm has “Neutral” rating given on Tuesday, May 10 by SunTrust. On Thursday, October 22 the stock rating was maintained by Barclays Capital with “Overweight”. The stock of St. Jude Medical, Inc. (NYSE:STJ) has “Buy” rating given on Tuesday, September 22 by UBS. The stock of St. Jude Medical, Inc. (NYSE:STJ) has “Buy” rating given on Friday, January 8 by Suntrust Robinson. The stock has “Equal-Weight” rating given by Morgan Stanley on Monday, May 2.

According to Zacks Investment Research, “St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.”

Insitutional Activity: The institutional sentiment decreased to 0.69 in 2016 Q2. Its down 0.17, from 0.86 in 2016Q1. The ratio is negative, as 73 funds sold all St. Jude Medical, Inc. shares owned while 218 reduced positions. 108 funds bought stakes while 143 increased positions. They now own 256.31 million shares or 7.42% more from 238.60 million shares in 2016Q1.
Conning holds 6,753 shares or 0.02% of its portfolio. Signaturefd accumulated 0% or 373 shares. The Arizona-based Arizona State Retirement has invested 0.08% in St. Jude Medical, Inc. (NYSE:STJ). Next Fincl Gru holds 0.11% or 4,550 shares in its portfolio. First Republic Invest Mngmt Inc reported 5,036 shares or 0% of all its holdings. Turner Invests Limited Partnership reported 28,400 shares or 0.69% of all its holdings. Endurant Cap Management L P accumulated 121,282 shares or 3.16% of the stock. Moreover, Vertex One Asset has 5.54% invested in St. Jude Medical, Inc. (NYSE:STJ) for 439,077 shares. Scotia Cap accumulated 45,355 shares or 0.07% of the stock. Shinko Asset Mngmt has 740 shares for 0% of their US portfolio. Two Sigma Securities Limited Liability Company last reported 5,307 shares in the company. Dimensional Fund Advsrs L P reported 1.10 million shares or 0.05% of all its holdings. Macquarie Grp Inc Limited last reported 93,121 shares in the company. Goldman Sachs has 0.14% invested in the company for 5.52M shares. Cohen Klingenstein Ltd Com has 0.12% invested in the company for 8,260 shares.

St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The company has a market cap of $22.47 billion.

STJ Company Profile

St. Jude Medical, Inc., incorporated on May 12, 1976, is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company’s product categories include tachycardia implantable cardioverter defibrillator (ICD) systems; atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker (pacemaker) systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders), and Thoratec products (ventricular assist devices and percutaneous heart pumps).

More recent St. Jude Medical, Inc. (NYSE:STJ) news were published by: Reuters.com which released: “EU regulator conditionally approves Abbott’s purchase of St Jude” on November 23, 2016. Also Businesswire.com published the news titled: “St. Jude Medical HeartMate 3 LVAS Demonstrated Improved Clinical Outcomes for …” on November 16, 2016. Businesswire.com‘s news article titled: “St. Jude Medical Shareholders Approve Merger with Abbott” with publication date: October 26, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment